Hepatitis B
Coverage of the 2017 EASL International Liver Conference
- Details
- Category: Hepatitis B
- Published on Sunday, 30 April 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2017 International Liver Congress, annual meeting of the European Society for the Study of the Liver (EASL), April 19-23, 2017, in Amsterdam
Full coverage listing by topic
International Liver Congress website
4/30/17
EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress
- Details
- Category: HBV Treatment Guidelines
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.
AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?
- Details
- Category: HBV Disease Progression
- Published on Wednesday, 15 February 2017 00:00
- Written by Liz Highleyman
The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among chronic hepatitis B patients treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD Liver Meeting in Boston. However, liver cancer remains a major indication for liver transplants and has a negative effect on survival of people with hepatitis B.
EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: Approved HBV Drugs
- Published on Tuesday, 25 April 2017 00:00
- Written by Liz Highleyman
People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the EASL International Liver Congress last week in Amsterdam.
Coverage of the 2016 AASLD Liver Meeting
- Details
- Category: Hepatitis B
- Published on Thursday, 02 February 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of the 2016 Liver Meeting, annual conference of the American Association for the Study of Liver Diseases, AASLD), November 11-15, 2016, in Boston.
EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 20 April 2017 00:00
- Written by Liz Highleyman
The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.
AASLD 2016: Lonafarnib Lowers Hepatitis Delta Levels with Acceptable Side Effects
- Details
- Category: Experimental HBV Drugs
- Published on Monday, 23 January 2017 00:00
- Written by Liz Highleyman
The hepatitis delta virus (HDV) assembly inhibitor lonafarnib reduces HDV viral load and can be safely boosted with ritonavir to allow for higher and more effective doses with acceptable gastrointestinal side effects, according to study results presented at the recent AASLD Liver Meeting in Boston.
EASL 2017: International Liver Congress Starts This Week in Amsterdam
- Details
- Category: HBV Treatment
- Published on Thursday, 13 April 2017 00:00
- Written by Liz Highleyman
The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at aidsmap.com will be providing on-site coverage of meeting highlights.
7. Tenofovir Alafenamide Approved for Hepatitis B
- Details
- Category: HBV Treatment
- Published on Thursday, 22 December 2016 00:00
- Written by HIVandHepatitis.com
In November the U.S. Food and Drug Administration (FDA) approved tenofovir alafenamide (TAF) for the treatment of hepatitis B, offering a new option that is easier on the bones and kidneys than the older version of tenofovir.
More Articles...
- AASLD 2016: Nivolumab Shows Good Safety and Promising Response Rates in Liver Cancer Study
- AASLD 2016: GS-4774 Therapeutic Vaccine Shows Little Efficacy in People with Hepatitis B
- AASLD 2016: Nucleic Acid Polymers Reduce HBsAg Levels and Improve Control of Hepatitis B Virus
- Coverage of the 2016 AASLD Liver Meeting
- AASLD 2016: Tenofovir Alafenamide Approved for Hepatitis B, Works Well with Less Effect on Bones
Web Design and Development by